Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Caregivers and Compounding Pharmacies: Identifying Unmet Needs
Epilepsy/Clinical Neurophysiology (EEG)
P16 - Poster Session 16 (5:30 PM-6:30 PM)
12-008
The objective of this study is to characterize caregivers' experiences with using compounding pharmacies and creating new formulations of medications at home.

The United States Food and Drug Administration has raised concerns about the quality of compounded medicines.  People with developmental disabilities or feeding tubes may require liquid formulations throughout the lifespan and have no choice but to use compounding pharmacies or reformulate medications at home through do-it-yourself (DIY) approaches.




Report: Limited FDA Survey of Compounded Drug Products. (2018, June 21). Retrieved October 11, 2019, from https://www.fda.gov/drugs/human-drug-compounding/report-limited-fda-survey-compounded-drug-products.

An online survey of caregivers of people with disabilities was performed to assess experiences with compounding pharmacies and DIY techniques.  Participants were recruited through social media groups representing more than 10,000 unique caregivers.

Forty-four caregivers of people with disabilities from seven months to 22 years old responded: 48% use feeding tubes.  Respondents compounded 8 different medications and modified 19 medications with DIY methods.  74% of caregivers who responded have a bachelor’s degree or higher; the majority identify as white/Caucasian (92%). The most commonly reported diagnoses include “epilepsy/seizures” (74%), cerebral palsy (35%), and autism spectrum disorder (13%). 

Caregivers expressed concerns about pharmacy wait times (50%), lack of health insurance coverage for compounding (50%), unavailability of local services (38%), conflicting information on storage conditions (27%), quality (27%), and conflicts with diet (23%).  Concerns about DIY methods included altering medication quality or dose (56%) and complications with mixing in food or drink (33%).


Ongoing challenges and concerns with compounding pharmacy and DIY solutions represent a significant quality of life burden that may also have serious clinical implications.  There remains a large unmet need for affordable, accessible, and high-quality liquid formulations of medications.  A larger study should be conducted to address the specific needs of the subpopulations in our study.

Authors/Disclosures

PRESENTER
No disclosure on file
Orrin Devinsky, MD, FÂé¶¹´«Ã½Ó³»­ (NYU Epilepsy Center) Dr. Devinsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Devinsky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for California Cannabis Enterprises. Dr. Devinsky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Engage. Dr. Devinsky has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Privateer Holdings. Dr. Devinsky has received personal compensation in the range of $1,000,000+ for serving on a Scientific Advisory or Data Safety Monitoring board for Receptor Holdings. Dr. Devinsky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rettco. Dr. Devinsky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Silver Spike. Dr. Devinsky has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tevard. Dr. Devinsky has received personal compensation in the range of $1,000,000+ for serving on a Scientific Advisory or Data Safety Monitoring board for Tilray. Dr. Devinsky has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Engage. Dr. Devinsky has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Tevard Biosciences. Dr. Devinsky has stock in Engage. Dr. Devinsky has stock in Empatica. Dr. Devinsky has stock in California Cannabis Enterprises. Dr. Devinsky has stock in Empatica. Dr. Devinsky has stock in Silver Spike. Dr. Devinsky has stock in Docklight Brands. Dr. Devinsky has stock in Egg Rock/Papa Barkley. Dr. Devinsky has stock in Leafly. Dr. Devinsky has stock in Left Coast Ventures. Dr. Devinsky has stock in Privateer Holdings. Dr. Devinsky has stock in Receptor Holdings. Dr. Devinsky has stock in Qstate. The institution of Dr. Devinsky has received research support from GW Pharma. The institution of Dr. Devinsky has received research support from Zogenix. The institution of Dr. Devinsky has received research support from PTC Pharma. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from DOD. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from Epilepsy Foundation. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from NSF. Dr. Devinsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Devinsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Devinsky has received publishing royalties from a publication relating to health care.
Kathryn A. Hart, RN No disclosure on file